This is the text extract for April Tender Notification - Correction; Contact: Notifications; Posted: 2012-05-01, browse documents here.
1 May 2012
TENDER RESULT CORRECTION – CABERGOLINE TABLETS
On 30 April 2012, we notified a number of decisions relating to the 2010/11 and 2011/12 Invitation to Tender. The notification contained an error relating to cabergoline tablets. The notification should have shown only Dostinex (Pfizer) as the “Sole supply brand (Supplier)” and Arrow-Cabergoline (Arrow) only as the “Brand (Supplier) affected by reference pricing and delisting”. The corrections are shown in the table below. We apologise for any inconvenience this may have caused. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.
2011/12 Tender – Sole Subsidised Supply Status applies until 30 June 2015 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows: Chemical Name Presentation; Pack size and type Tab 0.5 mg; 2 tablets, glass bottle Tab 0.5 mg; 8 tablets, glass bottle Current New subsidy subsidy and and price price $16.50 $66.00 $6.25 $25.00 Sole supply brand (Supplier) Dostinex (Pfizer) Dostinex (Pfizer) Date of listing/subsidy change for tender winning brand 1 July 2012 1 July 2012 Date of reference pricing of other listed brands 1 September 2012 1 September 2012 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 December 2012 1 December 2012 Arrow-Cabergoline (Arrow) Arrow-Cabergoline (Arrow)
A505072 - qA21977
1 May 2012 TENDER RESULT CORRECTION – CABERGOLINE TABLETS On 30 April 2012, we notified a number of decisions relating to the 2010/11 and 2011/12 Invitation to Tender. The notification contained an error relating to cabergoline tablets. The notification should…
This text has been extracted from the source PDF document.
Also available as plain text.
Please contact webmaster to discuss alternative format options.